Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients' sera by HPLC and is inducible by IFN-γ
复制标题
DOI：
10.1016/j.leukres.2008.06.014
复制
发表时间：
2009-03-01
影响因子：
2.7
通讯作者：
Quesnel, Bruno
中科院分区：
文献类型：
--
作者：
Corm, Selim;Berthon, Celine;Quesnel, Bruno
吲哚胺 2,3-双加氧酶 (IDO) 将色氨酸转化为犬尿氨酸，阻断 T 细胞激活并诱导免疫抑制。急性髓性白血病 (AML) 患者的血清犬尿氨酸/色氨酸比值 (Kyn/Trp) 升高，表明 IDO 活性高于健康人。 Kyn/Trp 比率较高的患者生存率较低。在体外暴露于 IFN-γ 后，在 AML 细胞中也检测到了 IDO 活性，这表明 AML 患者血清中较高的 Kyn/Trp 比率可能是由于刺激的白血病母细胞造成的。因此，在AML中，可以轻松监测IDO的活性，为未来IDO阻断药物的临床测试提供工具。 (c) 2008 Elsevier Ltd. 保留所有权利。
The enzyme indoleamine 2,3-dioxygenase (IDO) converts tryptophan to kynurenine, blocking T-cell activation and inducing immunosuppression. In patients with acute myeloid leukemia (AML), the serum kynurenine/tryptophan ratio (Kyn/Trp) was raised, suggesting a higher IDO activity than in healthy people. Patients with higher Kyn/Trp ratios showed lower survival. IDO activity was also detected in AML cells after exposure to IFN-gamma in vitro, suggesting that the higher Kyn/Trp ratio in serum of AML patients might have resulted from stimulated leukemic blast cells. Thus, in AML, the activity of IDO can be easily monitored, providing a tool for future clinical testing of IDO-blocking drugs. (c) 2008 Elsevier Ltd. All rights reserved.